

Liste des publications depuis 2015

2021

1. Bouery C, Azeroual L, Hufnagel G, Vrtovsni F, Goffin É. [Peritoneal dialysis catheter sterilization by urokinase administration in case of relapsing peritonitis: About four observations]. *Nephrol Ther.* 2021;17:128-131. doi:10.1016/j.nephro.2020.09.008
2. Bover J, Bosch R, Ureña P, et al. Kidneys also speak Spanish. *Nefrol (Engl Ed).* 2021;41:225-226. doi:10.1016/j.nefro.2020.11.002
3. Bover J, Ureña-Torres P, Cozzolino M, Rodríguez-García M, Gómez-Alonso C. The Non-invasive Diagnosis of Bone Disorders in CKD. *Calcif Tissue Int.* 2021;108:512-527. doi:10.1007/s00223-020-00781-5
4. Cailleaux PE, Ostertag A, Metzger M, et al. Longitudinal Bone Loss Occurs at the Radius in CKD. *Kidney Int Rep.* 2021;6:1525-1536. doi:10.1016/j.ekir.2021.03.874
5. Clerte M, Philip R, Levi C, et al. Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis. *Scand J Rheumatol.* Published online 2021:1-9. doi:10.1080/03009742.2021.1920120
6. Daulasim A, Seris P, Maheas C, Hude I, Ridet C, Touzot M. Feasibility and outcomes of native arteriovenous fistula in octogenarians. *Clin Nephrol.* 2021;95(3):136-142. doi:10.5414/CN110128
7. Guerraoui A, Idier L, Hallonet P, et al. Psychological impact of lockdown and the COVID-19 epidemic on haemodialysis patients and carers in France. *Nephrol Ther.* 2021;(xxxx). doi:10.1016/j.nephro.2021.02.006
8. Lombardi Y, Hiesse C, Ridet C, Touzot M. From combined heart-kidney to kidney transplantation program: What nephrologists should know about dilated cardiomyopathy. *Transpl Int.* Published online 2021. doi:10.1111/tri.13922
9. Luque Y, Jamme M, Aubert O, et al. A kidney discard decision strategy based on zero-time histology analysis could lead to an unjustified increase in the organ turn-down rate among ECD. *Transpl Int.* Published online 2021. doi:10.1111/tri.13933
10. Mutinelli-Szymanski P, Hude I, Merle E, et al. Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients. *Clin Kidney J.* 2021;14:124-131. doi:10.1093/ckj/sfaa194
11. Petitclerc T, Ridet C. Routine online assessment of dialysis dose: Ionic dialysance or UV-absorbance monitoring? *Semin Dial.* 2021;34:116-122. doi:10.1111/sdi.12949
12. Pimentel A, Ureña-Torres P, Bover J, Luis Fernandez-Martín J, Cohen-Solal M. Bone Fragility Fractures in CKD Patients. *Calcif Tissue Int.* 2021;108:539-550. doi:10.1007/s00223-020-00779-z
13. Pimentel A, Bover J, Elder G, Cohen-Solal M, Ureña-Torres PA. The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)-A Systematic Review. *Diagnostics (Basel).* 2021;11(5). doi:10.3390/diagnostics11050772

14. Reach P, Touzot M, Lombardi Y, et al. Electrochemical skin conductance by Sudoscan V R : a new tool to predict intradialytic hypotension. *Nephrol Dial Transpl*. Published online 2021;1-8. doi:10.1093/ndt/gfab183
15. Sukul N, Karaboyas A, Csomor PA, et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. *Kidney Med*. 2021;3:42-53.e1. doi:10.1016/j.xkme.2020.08.011
16. Tabibzadeh N, Karaboyas A, Robinson BM, et al. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. *Nephrol Dial Transpl*. 2021;36:160-169. doi:10.1093/ndt/gfaa195
17. Verney C, Pierrel B, Le Flécher A, et al. Patient's therapeutic education on renin-angiotensin system inhibitors could limit iatrogenic acute kidney injuries. The RASlzen study. *Therapie*. 2021;76:494-497. doi:10.1016/j.therap.2020.07.004
18. Vigneron C, Jamme M, Schurder J, et al. Efficacy and tolerance of sustained low-efficiency dialysis with calcium-free citrate-containing dialysate anticoagulation. *Clin Kidney J*. 2021;14:1025-1026. doi:10.1093/ckj/sfaa128
19. Villié P, Dauvergne M, Maheas C, et al. Clinical outcome of short daily hemodialysis in the elderly. *J Nephrol*. Published online 2021. doi:10.1007/s40620-021-01148-1

2020

1. Cohen-Solal M, Funck-Brentano T, Torres PU. Bone fragility in patients with chronic kidney disease. *Endocr Connect*. 2020;9(4):R93-R101. doi:10.1530/EC-20-0039
2. Bover J, Molina P, Ureña-Torres P, Arenas MD. Feasible Low-Phosphorus Dietary Patterns in Maintenance Hemodialysis Patients: Need for Original Research. *Kidney Int Rep*. 2020;5:1845-1847. doi:10.1016/j.ekir.2020.09.008
3. Benillouche E, Ostertag A, Marty C, Ureña Torres P, Cohen-Solal M. Cortical Bone Microarchitecture in Dialysis Patients. *Am J Nephrol*. 2020;51(10):833-838. doi:10.1159/000510064
4. Bushinsky DA, Chertow GM, Cheng S, et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. *Nephrol Dial Transplant*. 2020;35(10):1769-1778. doi:10.1093/ndt/gfz039
5. Bover J, Ureña-Torres P, Mateu S, et al. Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? *Clin Kidney J*. 2020;13(4):513-521. doi:10.1093/ckj/sfz187
6. Mazzaferro S, De Martini N, Rotondi S, et al. Bone, inflammation and chronic kidney disease. *Clin Chim Acta*. 2020;506:236-240. doi:10.1016/j.cca.2020.03.040
7. Ensergueix G, Pallet N, Joly D, et al. Ifosfamide nephrotoxicity in adult patients. *Clin Kidney J*. 2020;13(4):660-665. doi:10.1093/CKJ/SFZ183
8. Lacroix JS, Urena-Torres P. Potential application of fibroblast growth factor 23-klotho axis in chronic kidney disease. *Nephrol Ther*. 2020;16(2):83-92. doi:10.1016/j.nephro.2019.05.003

9. Touzot M, Lefebvre T, Maheas C, Ridel C, Puy H, Karim Z. A hepcidin-based approach for iron therapy in hemodialysis patients: A pilot study. *Hemodial Int*. 2020;24(2):188-194. doi:10.1111/hdi.12823
10. Ureña-Torres P, D'Marco L, Raggi P, et al. Valvular heart disease and calcification in CKD: More common than appreciated. *Nephrol Dial Transplant*. 2021;35(12):2046-2053. doi:10.1093/NDT/GFZ133
11. Touzot M, Seris P, Maheas C, et al. Mathematical model to predict B-type natriuretic peptide levels in haemodialysis patients. *Nephrology*. 2020;25(1):82-89. doi:10.1111/nep.13586
12. Ossman R, Jamme M, Moulin B, et al. Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL Study. *Transplantation*. 2020;104:1256-1262. doi:10.1097/TP.0000000000002937
13. Assayag M, Levy D, Seris P, et al. Relative Change of Protidemia Level Predicts Intradialytic Hypotension. *J Am Heart Assoc*. 2020;9(1). doi:10.1161/JAHA.119.014264

2019

1. Schurder J, Morel P, Blanc J, Clerté M, Ridel C, Touzot M. Skin lesions and vancomycin use in a hemodialysis patient. *Hemodial Int*. 2019;23(4):E127-E129. doi:10.1111/hdi.12786
2. Bennis Y, Cluet Y, Titeca-Beauport D, et al. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *Toxins (Basel)*. 2019;11(5). doi:10.3390/toxins11050279
3. Touzot M, Lefebvre T, Roux A, et al. Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. *Nephrology*. 2019;24(7):751-757. doi:10.1111/nep.13485
4. Rostoker G, Loridon C, Griuncelli M, et al. Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study. *EBioMedicine*. 2019;39:461-471. doi:10.1016/j.ebiom.2018.11.020
5. Martín-Núñez E, Donate-Correa J, Kannengiesser C, et al. A Novel Heterozygous Deletion Variant in KLOTHO Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway. *J Clin Med*. 2019;8(4):500. doi:10.3390/jcm8040500
6. Marques C, Carvelli J, Biard L, et al. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A multicenter study of 119 patients. *Front Immunol*. 2019;10(JULY):1665. doi:10.3389/fimmu.2019.01665
7. Rottembourg J, Ureña-Torres P, Toledano D, et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. *Clin Kidney J*. 2019;12:871-879. doi:10.1093/ckj/sfz021
8. Cunningham J, Block GA, Chertow GM, et al. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. *Kidney Int Reports*. 2019;4(7):987-994. doi:10.1016/j.ekir.2019.04.010

9. Petitclerc T, Gaillard F. The different modalities of isonatric hemodialysis. *Nephrol Ther.* 2019;15(1):22-28. doi:10.1016/j.nephro.2018.03.005
10. Ureña-Torres PA, Vervloet M, Mazzaferro S, et al. Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. *Clin Kidney J.* 2019;12:269-280. doi:10.1093/ckj/sfy061
11. Ayari H, Pasquier F, El Karoui K, et al. Myelodysplastic Syndrome in Hemodialysis Patients. *Kidney Int Reports.* 2019;4(8):1175-1178. doi:10.1016/j.ekir.2019.05.002
12. Donate-Correa J, Tagua VG, Ferri C, et al. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. *J Clin Med.* 2019;8(3):287. doi:10.3390/jcm8030287
13. Bover J, Ureña-Torres P, Laiz Alonso AM, et al. Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. *Nefrol (Engl Ed).* 2019;39:227-242. doi:10.1016/j.nefro.2018.10.009
14. Comarmond C, Lorin V, Marques C, et al. TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. *J Hepatol.* 2019;71(5):908-919. doi:10.1016/j.jhep.2019.06.029
15. Bataille S, Bon J, Kolko A, et al. Daily practices of protein energy wasting management in hemodialysis patients: A French national survey. *Nephrol Ther.* 2019;15(3):136-142. doi:10.1016/j.nephro.2018.11.008

2018

1. Alculumbre SG, Saint-André V, Di Domizio J, et al. Diversification of human plasmacytoid predendritic cells in response to a single stimulus. *Nat Immunol.* 2018;19:63-75. doi:10.1038/s41590-017-0012-z
2. Bover J, Ureña-Torres P, Torregrosa J V, et al. Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. *Nefrol (Engl Ed).* 2018;38:476-490. doi:10.1016/j.nefro.2017.12.006
3. Bover J, Ureña P, Aguilar A, et al. Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. *Calcif Tissue Int.* 2018;103:111-124. doi:10.1007/s00223-018-0399-z
4. Cambier A, Rabant M, Peuchmaur M, et al. Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features. *Kidney Int Rep.* 2018;3:916-925. doi:10.1016/j.ekir.2018.03.013
5. Chauveau P, Aparicio M, Bellizzi V, et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease. *Nephrol Dial Transpl.* 2018;33:725-735. doi:10.1093/ndt/gfx085
6. Ensergueix G, Karras A. [Ifosphamide nephrotoxicity]. *Nephrol Ther.* 2018;14 Suppl 1:S125-S131. doi:10.1016/j.nephro.2018.02.008
7. Gaillard F, Petitclerc T. From Isonatric to Isotonic Hemodialysis. *Blood Purif.* 2018;46(1):77-80. doi:10.1159/000487540

8. Mazzaferro S, Cianciolo G, De Pascalis A, et al. Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know? *Nephrol Dial Transpl.* 2018;33:2092-2100. doi:10.1093/ndt/gfy115
9. Mercadal L, Tezenas du Montcel S, Chonchol MB, et al. Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial. *Am J Nephrol.* 2018;48:349-356. doi:10.1159/000494338
10. Petittclerc T. [Technological innovations in dialysis]. *Nephrol Ther.* 2018;14:6S1-6S6. doi:10.1016/S1769-7255(18)30644-8
11. Ureña-Torres PA, Cozzolino M, Bover J. [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease]. *Nephrol Ther.* 2018;14:189-200. doi:10.1016/j.nephro.2017.03.003

2017

1. Johansson L, Fouque D, Bellizzi V, et al. As we grow old: nutritional considerations for older patients on dialysis. *Nephrol Dial Transpl.* 2017;32:1127-1136. doi:10.1093/ndt/gfw201
2. Kissling S, Legallais C, Pruijm M, et al. A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges. *BMC Nephrol.* 2017;18:81. doi:10.1186/s12882-017-0494-9
3. Ridel C, Kissling S, Mesnard L, Hertig A, Rondeau É. [Plasma exchange in nephrology: Indications and technique]. *Nephrol Ther.* 2017;13:43-55. doi:10.1016/j.nephro.2016.12.002
4. Rosenzweig M, Languille E, Debiec H, et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. *Kidney Int.* 2017;92:227-237. doi:10.1016/j.kint.2017.01.012
5. Touzot M, Terrier CS, Faguer S, et al. Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus: A historical study of 12 adult patients. *Med.* 2017;96:e9017. doi:10.1097/MD.00000000000009017
6. Tran Ba SN, Lidove O, Dorent R, et al. [Combined heart and kidney transplantation in Fabry's disease: Long-term outcomes in two patients]. *Rev Med Interne.* 2017;38:137-142. doi:10.1016/j.revmed.2016.03.008
7. Vigneau C, Kolko A, Stengel B, et al. Ten-years trends in renal replacement therapy for end-stage renal disease in mainland France: Lessons from the French Renal Epidemiology and Information Network (REIN) registry. *Nephrol Ther.* 2017;13:228-235. doi:10.1016/j.nephro.2016.07.453

2016

1. Batista da Costa J, Cornu JN, Levgraverend D, et al. Pyonephrosis Caused by Salmonella Typhi: A Case Report. *Urol Int.* 2016;96:241-243. doi:10.1159/000360741
2. Commereuc M, Weill FX, Loukiadis E, et al. Recurrent Hemolytic and Uremic Syndrome Induced by Escherichia Coli. *Med.* 2016;95:e2050. doi:10.1097/MD.0000000000002050

3. Luque Y, Bataille A, Taldir G, Rondeau É, Ridel C. [Cardiac arrest in dialysis patients: Risk factors, preventive measures and management in 2015]. *Nephrol Ther.* 2016;12:6-17. doi:10.1016/j.nephro.2015.06.008
4. Messika J, Stoclin A, Bouvard E, et al. The Challenging Diagnosis of Non-Community-Acquired Pneumonia in Non-Mechanically Ventilated Subjects: Value of Microbiological Investigation. *Respir Care.* 2016;61:225-234. doi:10.4187/respcare.04143
5. Pladys A, Bayat S, Kolko A, Béchade C, Couchoud C, Vigneau C. French patients on daily hemodialysis: clinical characteristics and treatment trajectories. *BMC Nephrol.* 2016;17:107. doi:10.1186/s12882-016-0306-7

2015

1. Al Gain M, Crickx B, Bejar C, et al. [Sirolimus-induced lymphedema in a kidney-transplant recipient: Partial recovery after changeover to tacrolimus]. *Ann Dermatol Venerol.* 2015;142:350-355. doi:10.1016/j.annder.2015.01.020
2. Gaillard F, Laplanche S, Petitclerc T. Natrema, tonicity, and conductivity measurements in hemodialyzed patients. *Int J Artif Organs.* 2015;38:288-290. doi:10.5301/ijao.5000409
3. Mercadal L, Franck JE, Metzger M, et al. Improved survival associated with acetate-free haemodialysis in elderly: a registry-based study. *Nephrol Dial Transpl.* 2015;30:1560-1568. doi:10.1093/ndt/gfv248
4. Panaye M, Kolko-Labadens A, Lasseur C, et al. Phenotypes influencing low physical activity in maintenance dialysis. *J Ren Nutr.* 2015;25:31-39. doi:10.1053/j.jrn.2014.07.010
5. Touzot M, Cacoub P, Bodaghi B, Soumelis V, Saadoun D. IFN- α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. *Autoimmun Rev.* 2015;14:370-375. doi:10.1016/j.autrev.2014.12.009
6. Touzot M, Couvrat-Desvergnès G, Castagnet S, et al. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. *Transplantation.* 2015;99:63-68. doi:10.1097/TP.0000000000000285
7. Touzot M, Dahirel A, Cappuccio A, Segura E, Hupé P, Soumelis V. Using Transcriptional Signatures to Assess Immune Cell Function: From Basic Mechanisms to Immune-Related Disease. *J Mol Biol.* 2015;427:3356-3367. doi:10.1016/j.jmb.2015.05.006
8. Touzot M, Poisson J, Faguer S, et al. Rituximab in anti-GBM disease: A retrospective study of 8 patients. *J Autoimmun.* 2015;60:74-79. doi:10.1016/j.jaut.2015.04.003
9. Vinsonneau C, Allain-Launay E, Blayau C, et al. Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). *Ann Intensive Care.* 2015;5:58. doi:10.1186/s13613-015-0093-5